Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-01

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) has become a big challenge all over the world. Most patients are not available to curative resection when first diagnosed. There are a variety of treatment options for advanced HCC. However, due to the heterogeneity of HCC, the overall response rate (ORR) is not high for systemic therapies. Therefore, appropriate selection of patients who are suitable for individual systemic therapies is important for clinical decision-making.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.

NCT07101237

Hepatocellular Carcinoma (HCC) Intrahepatic Cholangiocarcinoma (ICC) Primary Liver Cancer

RECRUITING

Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

NCT07059936

Hepatocellular Carcinoma (HCC)

RECRUITING

Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS

NCT06590948

Liver Cancer

RECRUITING

Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC

NCT04212286

Hepatocellular Cancer Liver Cirrhoses Diagnoses Disease

COMPLETED NA

CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma

NCT04715321

Hepatocellular Carcinoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although major achievements have been acquired in diagnosis and treatment, the prognosis of hepatocellular carcinoma (HCC) is still unsatisfactory. Liver resection remains the main curative treatment for HCC, but most patients are at an advanced stage when first diagnosed, leading to be not available to curative therapies. There is a variety of treatment options for advanced HCC, such as transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), targeted therapy (sorafenib and lenvatinib), immunotherapy, and the combination of different therapies. However, due to the heterogeneity of HCC, different patients respond differently to systemic therapies. The the overall response rate (ORR) is not satisfactory and most patients can not benefit from the systemic therapies. There is an urgent need to identify patients who are likely to have positive response to systemic therapies at the beginning before treatment. Therefore ,we want to collect the clinical information of patients with advanced HCC treated with systemic therapies, including demographic data , laboratory index, histological features, radiomics data. Patients are followed-up at a interval of 1 month after treatment, and the ORR, overall survival (OS), progression-free survival (PFS) are recorded. Then the treatment response are evaluated and the relationship between the clinical data and efficacy of systemic therapies are explored by machine learning methods. Then models based on clinical features or radiomics features are developed to predict response to different systemic therapies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma Non-resectable Effect of Drug

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with response to systemic therapies

Patients shown complete response (CR) and partial response (PR) after treatments. The clinical data and radiomics data are collected through electronic medical record system.

radiological evaluation

Intervention Type DIAGNOSTIC_TEST

All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.

patients with no response to systemic therapies

Patients shown progressive disease (PD) and stable disease (SD) after treatments. The clinical data and radiomics data are collected through electronic medical record system.

radiological evaluation

Intervention Type DIAGNOSTIC_TEST

All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

radiological evaluation

All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinically or pathologically diagnosed HCC
* Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-2
* Child-Pugh score of ≤7
* complete clinical and follow-up information
* evaluable efficacy after treatment
* age between 18-80 years old

Exclusion Criteria

* with other malignancies
* Eastern Cooperative Oncology Group performance status (ECOG-PS) \>2
* Child-Pugh score of \>7
* incomplete clinical data
* lost to follow up
* unevaluable efficacy after treatment
* age \<18 years old or \>80 years old

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No